Home › Non-Hodgkin Lymphoma › Massachusetts › Boston
Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma sa Boston, MA
26 pag-aaral para sa Non-Hodgkin Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Boston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Nagre-recruitPhase 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Nagre-recruitPhase 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Nagre-recruitObservasyonal na pag-aaral
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Nagre-recruitObservasyonal na pag-aaral
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Nagre-recruit
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Nagre-recruitPhase 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Nagre-recruitPhase 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Nagre-recruitPhase 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pag-aaral para sa Non-Hodgkin Lymphoma sa ibang lungsod
- New York City, NY31 pag-aaral
- Houston, TX31 pag-aaral
- Nashville, TN21 pag-aaral
- Philadelphia, PA20 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Washington, DC18 pag-aaral
- Chicago, IL18 pag-aaral
- Atlanta, GA18 pag-aaral
- Milwaukee, WI18 pag-aaral
- Columbus, OH18 pag-aaral
- Dallas, TX17 pag-aaral
- Seattle, WA16 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso112 pag-aaral
- Non-Small Cell Lung Cancer90 pag-aaral
- Kanser (lahat ng uri)85 pag-aaral
- Metastatic Cancer63 pag-aaral
- Colorectal Cancer63 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Ovary61 pag-aaral
- Kanser sa Prostate59 pag-aaral
- Depression52 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Pagkabigo ng Puso44 pag-aaral
- Acute Myeloid Leukemia44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.